Management

BOARD OF DIRECTORS

The Board of Directors at AFYX Therapeutics A/S is composed of a diverse group of leaders, each bringing a wealth of experience and expertise from various sectors within and outside the pharmaceutical industry.

Our directors are distinguished by their backgrounds in medical research, global market strategy, regulatory compliance, financing and healthcare policy, ensuring a comprehensive approach to decision-making and strategic planning.

With a diverse representation and professional disciplines, our board reflects the global community we serve and brings a wide array of perspectives to our mission of improving health outcomes worldwide.

This diversity fosters innovative thinking and creative solutions to complex challenges, underpinning our commitment to ethical leadership and corporate responsibility.

BOARD OF DIRECTORS

DR. OLE BAADSGAARD

CHAIRMAN

Dr. Baadsgaard holds a MD degree from University of Aarhus and a DMSc degree from University of Copenhagen. He is a skilled scientist with expertise in translational research and drug development. Dr. Baadsgaard has previously been Chief Medical Officer in Both Genmab A/S and Y-mAbs Therapeutics, Inc. He has been an external Expert advisor to Bank Invest Biotech in their advisory Board and co-founder of Genmab A/S. He has been lead author or contributor to more than 100 peer-reviewed journal publications and author on more than 20 patents and pending patent applications.

DR. CLAUS J. MØLLER-SAN PEDRO

CEO, BOD MEMBER

Dr. Møller has his MD & PhD degrees from Copenhagen University. Dr. Møller is the Founder and CEO of our company. Previously Dr. Møller was Co-Founder and CEO of Y-mAbs, Inc and secured its IPO in 2018 as well as getting Danyelza FDA approved in 2020. Before this Dr. Møller was the CEO of Azanta A/S that was later sold to Norgine as well as being a Co-Founder and EVP & COO at Genmab and instrumental in its IPO. Dr. Møller also held a position as EVP & COO in OXiGENE, Inc. (OLTC) – a company that he was also securing a successful IPO In Stockholm in 1996.

MS. PIA LAURSEN

BOD MEMBER

Ms. Laursen brings +20 years of international experience as a strategic Manager and part of Executive Management, with focus on strategy, optimization and development of business models as well as sales and marketing strategies in LCG, B2B, B2C. Ms. Laursen has several years of BOD experience as well as a formal BOD education and brings significant commercial and marketing expertise to our board.

MR. SØREN KJÆR

BOD MEMBER

Mr. Kjær brings +30 years of international banking experience to our BOD – His background includes Venture Capital Investments and Board Positions in Life Science and Venture Capital companies, as well as a career with J.P Morgan and SEB. Mr. Kjær was a Partner at Novo Ventures, Managing Director, UBS and most recently CEO Nordics and Luxembourg for Quintet Private Bank.